The new guideline also recommends faster tapering to a lower dose of glucocorticoids and a longer duration of ...

The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

ImmuneOnco Biopharmaceuticals has received approval from China’s National Medical Products Administration for a Phase II ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists ...

Approval in lupus nephritis is expected to push the product above the $1 billion threshold and into blockbuster sales territory. Lupus nephritis is a severe form of SLE that can lead to late-stage ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

Joint replacement is less common in lupus. It may become necessary due to damage from the disease itself or from some of the drugs used to treat it. As with RA, the hips and knees are the most ...

BioNxt reports expansion of its next-generation product pipeline with innovative solutions for autoimmune diseases and longevity: Vancouver, BC Wednesday, November 27, 2024, 17:00 ...